3B Blackbio DX Ltd Share Price

Medical Accessories / DisposablesNSE
₹1,151.10
+7.30+0.64% (1D)
As on 21 Aug 2026 at 05:53
As of 21 Aug 2026 at 05:53, 3B Blackbio DX Ltd is trading at ₹1,151.10, with a market cap of ₹977.14 crore. At a P/E of 19.18 and a dividend yield of 0.44%, it is a small-cap stock in the Healthcare sector.

3BBLACKBIO Price Chart

Market Cap
₹977.14 Cr
PE Ratio
19.18
ROCE
20.81%

3B Blackbio DX Ltd Performance

3B Blackbio DX Ltd Fundamentals

Market Cap₹977.14 Cr
ROE15.46%
P/E Ratio (TTM)19.18
EPS (TTM)₹59.37
P/B Ratio3.06
Dividend Yield0.44%
Industry P/E177.95
Book Value₹371.72
Debt to Equity0.00
Face Value₹10

3B Blackbio DX Ltd Shareholding Pattern

Promoter41%
Foreign Institutions2.5%
Mutual Funds0%
Domestic Institutions2.1%
Public54.4%

3B Blackbio DX Ltd Financial Statements

No data for this view.

3B Blackbio DX Ltd Peer Comparison

StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Apollo Hospitals Enterprise Ltd
₹8,720.00
-30.00(-0.34%)
1,25,380.26,696.5 - 9,050.0
Max Healthcare Institute Ltd
₹998.70
1.70(+0.17%)
97,201.1
Manipal Health Enterprises Ltd
₹724.25
-20.55(-2.76%)
95,266.2
Fortis Healthcare Ltd
₹910.80
-0.50(-0.05%)
68,761.6
Aster DM Quality Care Ltd
₹761.40
-38.80(-4.85%)
66,369.1

About 3B Blackbio DX

3D Blackbio DX Limited, formerly known as Kilpest India Limited was incorporated on May 25, 1972 as one of India's leading agro-business companies. Thereafter, the holding Company, Kilpest India Limited got merged with 3B BlackBio Biotech India Limited and as per the Scheme of Amalgamation, the name of the Company was changed from Kilpest India Limited to 3B BlackBio DX Limited in August, 2023. The Company is a leading Indian biotech firm focused on molecular diagnostics (PCR kits, enzymes, reagents for diseases like cancer/ infectious diseases) under the 'TRUPCR' brand, alongside developing Next-Gen Sequencing (NGS) assays (TRUNGS) & Rapid Tests (TRURAPID), while continuing its traditional agrochemicals business (pesticides, bio-products), serving both labs and government sectors, driven by R&D for innovative solutions. The Company has representation in India in the field of agriculture business comprising crop protection, public health products and bio-products and is reputed reliable supplier to various Govt. organizations, such as Directorate General of Supplies & Transport, New Delhi, NAVY, Vishakapatnam/Mumbai, Food Corporation of India Raipur/ Bhopal/ Lucknow/ Mumbai/ Jaipur, NTPC, Bilaspur, Directorate of Health Service, M.P/Maharashtra/AP, Directorate of General Of Health Organization, Gujarat/U.P, Directorate General of Health services, MOH&FW (NVBDCP), Govt. of India, M/s Hindustan Latex Ltd, Noida, Director of Agriculture and Horticulture, M.P./Trivandrum, Central/Western Railway, Mumbai, Northern Railway, New Delhi etc. the company has nationwide distribution network of over 2000 dealers. It possess well equipped R&D laboratory duly approved and recognized by DSIR, Ministry of Science and Technology, Government of India. Advanced instrumentation facility supported by equally competent team of scientists and technicians lay down a strong R&D foundation. Clean and hygienic environment ensure the consistency and reliability of results. Laboratory studies are planned, performed, monitored, recorded, applied in small scale field and then tabulated. The products are manufactured to high International specifications with stringent quality control from raw material procurement to finished goods dispatch. The company's manufacturing process is complimented with the technical expertise and it has attained high standard suited to customer needs on 23-7-2002. Kilpest has received accreditation of International standard ISO 9001-2000 certified company. The companyhas diversified manufacturing in the field of micronutrients, bioproducts and plant growth regulators etc. The company is also exporting its products to Bangladesh and Afghanistan. In 2011-12, the Company launched Novel Biotech Indo-Spanish Joint Venture Project in Govindpura, Bhopal, Madhya Pradesh. It ventured into Diagnostic Service. In June, 2020, the Company launched , its single tube multiplex assay for TRUPCR SARS-CoV-2 RTqPCR Kit (Real-Time PCR based detection of SARS-CoV-2 virus) Version 3.2. With this, 3B BlackBio Biotech India Ltd. became first ever Indian molecular diagnostics company to receive US FDA-(EUA). Company launched NGS based 'TRUNGSr Solid Tumor Panel' for detection of SNVs, Indels, CNVs and RNA fusions in 35 marker genes and hotspots in 6 pharmocogenomics genes associated with solid tumors such as lung, gastro-intestinal/colorectal, breast, liver and ovarian tumors in FY 2024. The Rapid Kit manufacturing facility is made operational in 2025. The Company has added some novel products in Rapid Kit vertical for detection of Antimicrobial Resistance (AMR) genes. The Company has acquired Coris BioConcept SRL, Belgium in FY25.

Parent Organisation
Founded1972
Managing DirectorR K Dubey
NSE Symbol3BBLACKBIO

3B Blackbio DX Ltd Resistance and Support levels

R31,179.27R21,165.48R11,156.96S11,129.38S21,120.86S31,107.071,151.10

3B Blackbio DX Ltd Technicals

Current Price
₹1,151.10 ₹7.30 (+0.64%)
Bearish
10
Bullish
2
  • 20 Day4.3%
  • 50 Day5.8%
  • 100 Day6.5%
  • 200 Day6.5%

3B Blackbio DX Ltd Latest News

View More
05 AUG 2026 | Wednesday
3B BlackBio Dx Limited to convene a board meeting on August 13 to review financial results
30 MAY 2026 | Saturday
Board of 3B Blackbio DX recommends final dividend
21 MAY 2026 | Thursday
3B Blackbio DX to table results

2026

Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of 3B Blackbio DX Ltd is ₹1,151.10 as of 21 Aug 2026 at 05:53.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now